EAM
LEGN icon

Exome Asset Management’s Legend Biotech LEGN Stock Holding History

Exome Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,100
Closed -$1.03M – 86
2025
Q2 		$1.03M Buy
+29,100
New +$943K 0.77% 47
2025
Q1 		– Sell
-37,600
Closed -$1.22M – 70
2024
Q4 		$1.22M Sell
37,600
-9,400
-20% -$389K 0.92% 39
2024
Q3 		$2.29M Buy
+47,000
New +$2.5M 1.55% 27
2024
Q1 		– Sell
-37,900
Closed -$2.28M – 63
2023
Q4 		$2.28M Buy
+37,900
New +$2.4M 2.25% 17

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Exome Asset Management's LEGN Position: Q3 2025 in Review

Exome Asset Management sold out of Legend Biotech (LEGN) in Q3 2025, closing a stake of 29,100 shares — an estimated $1.03M sold.

Exome Asset Management first reported a position in LEGN in Q4 2023 and held it in 4 quarters. The position peaked at $2.29M in Q3 2024. 199 funds tracked by Wall St. Rank hold LEGN as of Q3 2025.

  • Exome Asset Management reported no remaining Legend Biotech position as of Q3 2025 after selling out during the quarter.
  • Exome Asset Management sold 29,100 Legend Biotech shares in Q3 2025, an estimated $1.03M.
  • Exome Asset Management first reported a position in Legend Biotech in Q4 2023 and held it in 4 quarters.
  • Exome Asset Management's Legend Biotech position peaked at $2.29M in Q3 2024.
  • 199 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.